TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
23
12
2019
accepted:
31
03
2020
revised:
26
03
2020
pubmed:
29
4
2020
medline:
22
12
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, we review checkpoint inhibitor signal pathways, resistance and sensitivity mechanisms, as well as response rates. We also investigate the correlation and response to ICI with BRCA1/2 mutation status and homologous recombination deficient tumors. Collectively we show that the use of tumor mutational burden may be effective as an emerging biomarker.
Identifiants
pubmed: 32341410
doi: 10.1038/s41417-020-0174-y
pii: 10.1038/s41417-020-0174-y
doi:
Substances chimiques
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-853Références
Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24(Suppl 5):743–50.
pubmed: 24782321
pmcid: 4009604
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(Suppl 6280):1463–9.
pubmed: 26940869
pmcid: 4984254
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(Suppl 6230):69–74.
pubmed: 25838375
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(Suppl 1):34.
pubmed: 5395719
pmcid: 5395719
Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science. 2018;362(Suppl 6411):eaar3593.
pubmed: 30309915
pmcid: 6718162
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4(Suppl 11):959–67.
pubmed: 27671167
pmcid: 5134329
Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(Suppl 2):202–6.
pubmed: 6365097
pmcid: 6365097
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl J Med. 2014;371(Suppl 23):2189–99.
pubmed: 25409260
pmcid: 4315319
Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, et al. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis Oncol. 2017;1:1–13.
Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(Suppl 7239):719.
pubmed: 19360079
pmcid: 2821689
Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria J-C, Postel-Vinay S. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22(Suppl 17):4309–21.
pubmed: 27390348
Chen Y-P, Zhang Y, Lv J-W, Li Y-Q, Wang Y-Q, He Q-M, et al. Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. Theranostics. 2017;7(Suppl 14):3585.
pubmed: 28912897
pmcid: 5596445
Liontos M, Anastasiou I, Bamias A, Dimopoulos M-A. DNA damage, tumor mutational load and their impact on immune responses against cancer. Ann. Transl. Med. 2016;4(Suppl 14):264.
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171(Suppl 5):1042–56.
pubmed: 29056344
pmcid: 5849393
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(Suppl 6):703.
pubmed: 28481359
pmcid: 5461196
Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(Suppl 7381):306.
pubmed: 22258609
pmcid: 3367003
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(Suppl 7463):415.
pubmed: 3776390
pmcid: 3776390
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(Suppl 11):1023.
pubmed: 24142049
pmcid: 24142049
Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol diagnostics. 2013;15(Suppl 5):607–22.
Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009;461(Suppl 7261):272.
pubmed: 19684571
pmcid: 2844771
Warr A, Robert C, Hume D, Archibald A, Deeb N, Watson M. Exome sequencing: current and future perspectives. G3: Genes, Genomes, Genet. 2015;5(Suppl 8):1543–50.
Baras AS, Stricker T. Characterization of total mutational burden in the GENIE cohort: Small and large panels can provide TMB information but to varying degrees. Cancer Res. 2017;77(Suppl 13):LB-105.
Gong J, Pan K, Fakih M, Pal S, Salgia R. Value-based genomics. Oncotarget. 2018;9(Suppl 21):15792.
pubmed: 29644010
pmcid: 5884665
Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.
pubmed: 29990692
D.I.S.C.O F. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. In: U.S. Food and Drug Administration. 2017.
Company B-MS. Prescribing information ipilimumab (Yervoy®). Princeton; 2018.
MERCK & CO. I. Prescribing Information Pembrolizumab (Keytruda®). Whitehouse Station; 2019.
Squibb B-M. Prescribing Information Nivolumab (Opdivo®). Princeton; 2019.
Regeneron Pharmaceuticals I. Prescribing information cemiplimab (Libtayo®). In: LCC S-AUS. NJ; 2019.
Genetech I. Prescribing information Atezolizumab (Tecentriq®). South San Francisco; 2019.
EMD Serono I. Prescribing information avelumab (Bavencio®). Rockland; 2019.
Pharmaceuticals A. Prescribing information durvalumab (Imfinzi®). Wilmington; 2018.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.
pubmed: 29644214
pmcid: 5883082
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(Supl 21):9543–53.
pubmed: 16227604
pmcid: 1265804
Jin H-T, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. In: Negative Co-Receptors and Ligands. Springer;2010. p. 17–37.
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J cancer. 2018;118(Suppl 1):9.
pubmed: 29319049
pmcid: 5765236
Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105(Suppl 52):20852–7.
pubmed: 19088198
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(Suppl 1):84.
pubmed: 17159987
Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(Suppl 9):915–9.
pubmed: 26272491
pmcid: 4560619
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(Suppl 4):252.
pubmed: 4856023
pmcid: 4856023
O’Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.
pubmed: 27951441
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(Suppl 4):707–23.
pubmed: 28187290
pmcid: 28187290
Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res. 2016;4(Suppl 3):194–203.
pubmed: 26787823
pmcid: 4775381
Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(Suppl 1):24.
pubmed: 24336101
Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol. 2008;8(Suppl 2):107.
pubmed: 18219309
Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39:147–64.
pubmed: 31099674
Kreiter S, Vormehr M, Van de Roemer N, Diken M, Löwer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(Suppl 7549):692.
pubmed: 25901682
pmcid: 4838069
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348(Suppl 6230):124–8.
pubmed: 25765070
pmcid: 4993154
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(Suppl 6257):207–11.
pubmed: 26359337
pmcid: 5054517
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate cancer prostatic Dis. 2015;18(Suppl 4):325.
pubmed: 26260996
pmcid: 4641011
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl J Med. 2012;366(Suppl 26):2443–54.
pubmed: 22658127
pmcid: 3544539
Korkolopoulou P, Kaklamanis L, Pezzella F, Harris A, Gatter K. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J cancer. 1996;73(Suppl 2):148.
pubmed: 8546899
pmcid: 2074307
Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, et al. Melanoma lesions independently acquire T-cell resistance during metastatic latency. Cancer Res. 2016;76(Suppl 15):4347–58.
pubmed: 27261508
Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019;25:389–4021.
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell–mediated immunotherapy. Cancer Discov. 2016;6(Suppl 2):202–16.
pubmed: 26645196
George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity. 2017;46(Suppl 2):197–204.
pubmed: 28228279
pmcid: 5408320
Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(Suppl 7559):231.
pubmed: 25970248
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76(Suppl 5):999–1008.
pubmed: 26833127
pmcid: 4775354
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(Suppl 6264):1084–9.
pubmed: 26541606
pmcid: 26541606
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(Suppl 6264):1079–84.
pubmed: 26541610
pmcid: 26541610
Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev cancer. 2008;8(Suppl 8):579.
pubmed: 18596824
Young MRI, Wright MA, Coogan M, Young ME, Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor β. Cancer Immunol, Immunother. 1992;35(Suppl 1):14–8.
Commeren DL, Van Soest PL, Karimi K, Löwenberg B, Cornelissen JJ, Braakman E. Paradoxical effects of interleukin‐10 on the maturation of murine myeloid dendritic cells. Immunology. 2003;110(Suppl 2):188–96.
pubmed: 14511232
pmcid: 1783045
Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and-extrinsic factors. Immunity. 2016;44(Suppl 6):1255–69.
pubmed: 27332730
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
pubmed: 18173375
Rudensky AY. Regulatory T cells and Foxp3. Immunological Rev. 2011;241(Suppl 1):260–8.
Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines. 2016;4(Suppl 3):28.
pmcid: 5041022
Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6(Suppl 3):1670–90.
pubmed: 25125485
pmcid: 4190561
Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(Suppl 237):237ra67–237ra67.
pubmed: 24848257
pmcid: 6980372
Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AR, Opyrchal M, et al. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 2014;193(Suppl 10):5327–37.
pubmed: 25320277
pmcid: 4225176
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl J Med. 2015;373(Suppl 1):23–34.
pubmed: 26027431
pmcid: 5698905
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl J Med. 2016;375(Suppl 19):1856–67.
pubmed: 27718784
pmcid: 5564292
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl J Med. 2015;373(Suppl 17):1627–39.
pubmed: 26412456
pmcid: 5705936
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl J Med. 2015;373(Suppl 2):123–35.
pubmed: 26028407
pmcid: 4681400
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl J Med. 2016;374(Suppl 26):2542–52.
pubmed: 27093365
pmcid: 4927341
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N. Engl J Med. 2015;372(Suppl 21):2018–28.
pubmed: 25891174
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl J Med. 2016;375(Suppl 19):1823–33.
pubmed: 27718847
Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(Suppl 10027):1540–50.
pubmed: 26712084
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl J Med. 2015;372(Suppl 26):2509–20.
pubmed: 26028255
pmcid: 4481136
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(Suppl 10066):255–65.
pubmed: 27979383
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(Suppl 10064):67–76.
pubmed: 27939400
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl J Med. 2015;372(Suppl 26):2521–32.
pubmed: 25891173
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl J Med. 2011;364(Suppl 26):2517–26.
pubmed: 21639810
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(Suppl 7):883–95.
pubmed: 27269741
Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(Suppl 5):275.
pubmed: 27079802
pmcid: 5381938
Ilie M, Hofman V, Dietel M, Soria J-C, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(Suppl 5):511–25.
pubmed: 26915032
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl J Med. 2015;373(Suppl 19):1803–13.
pubmed: 26406148
pmcid: 5719487
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(Suppl 35):3924.
pubmed: 29023213
pmcid: 6075826
Bhaijee F, Anders RA. PD-L1 expression as a predictive biomarker: Is absence of proof the same as proof of absence? JAMA Oncol. 2016;2(Suppl 1):54–5.
pubmed: 26561922
Soria J-C, Marabelle A, Brahmer JR, Gettinger S. Immune checkpoint modulation for non–small cell lung cancer. AACR;2015.
Barve M, Adams N, Plato L, Dupler R, Anand R, Jones J, et al. Case Report: immune checkpoint inhibitor elicited complete response in a heavily pretreated patient with metastatic endometrial carcinoma with a high tumor mutation burden (TMB). Mol Med: Curr Asp. 2017;1(Suppl 1):005.
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol cancer therapeutics. 2017;16(Suppl 11):2598–608.
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl J Med. 2017;377(Suppl 25):2500.
pubmed: 29262275
pmcid: 6549688
Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl J Med. 2018;378(Suppl 22):2093–104.
pubmed: 29658845
pmcid: 7193684
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer cell. 2018;33(Suppl 5):853–61.
pubmed: 29731394
pmcid: 6750707
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N. Engl J Med. 2017;376(Suppl 25):2415–26.
pubmed: 28636851
pmcid: 6487310
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl J Med. 2018;378(Suppl 21):1976–86.
pubmed: 29658848
pmcid: 6223617
Wang F, Wei X, Wang F, Xu N, Shen L, Dai G et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30:1479–1486.
Zhu J, Zhang T, Li J, Lin J, Liang W, Huang W, et al. Association between Tumor Mutation Burden (TMB) and outcomes of cancer patients treated with PD-1/PD-L1 inhibitions: a meta-analysis. Front Pharmacol. 2019;10:673.
pubmed: 31258479
pmcid: 6587434
Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016;1:16037.
pubmed: 27942391
pmcid: 5142752
Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Investig. 2016;126(Suppl 6):2334–40.
pubmed: 27159395
Johansson PA, Stark A, Palmer JM, Bigby K, Brooks K, Rolfe O, et al. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab. Immunogenetics. 2019;71(Suppl 5–6):433–6.
pubmed: 30714079
Saller J, Walko CM, Millis SZ, Henderson-Jackson E, Makanji R, Brohl AS. Response to checkpoint inhibitor therapy in advanced classic Kaposi sarcoma: a case report and immunogenomic study. J Natl Compr Cancer Netw. 2018;16(Suppl 7):797–800.
Mou H, Yu L, Liao Q, Hou X, Wu Y, Cui Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC cancer. 2018;18(Suppl 1):1105.
pubmed: 30419854
pmcid: 6233589
Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother cancer. 2017;5(Suppl 1):75.
pubmed: 28923100
pmcid: 5604145
Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, et al. Exceptional response to nivolumab and stereotactic body radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the center for personalized cancer therapy at UC San Diego Moores Cancer Center. Oncologist. 2017;22(Suppl 6):631–7.
pubmed: 28550027
pmcid: 5469598
Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L. Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017;2(Suppl 5):e000255.
pubmed: 29177095
pmcid: 5687552
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. JNCI: J Natl Cancer Inst. 1998;90(Suppl 15):1138–45.
pubmed: 9701363
Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immuneevasion and with reduced response to immunotherapy. Science. 2017;355(Suppl 6322):eaaf8399.
Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ.et al. Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer. Clin Cancer Res. 2019;0468:2018
Wen WX, Leong C-O. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS ONE. 2019;14(Suppl 4):e0215381.
pubmed: 31022191
pmcid: 6483182
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(Suppl 8):2930–40.
pubmed: 28650338
pmcid: 5531419
Dai Y, Sun C, Feng Y, Jia Q, Zhu B. Potent immunogenicity in BRCA1-mutated patients with highgradeserous ovarian carcinoma. J Cell Mol Med. 2018;22(Suppl 8):3979–86.
pmcid: 6050488
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(Suppl 12):13587–98.
pubmed: 26871470
pmcid: 4924663
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(Suppl 3):393–401.
pubmed: 30676622
pmcid: 6439837
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. In Proc. 50th Annual Meeting of the Society of Gynecologic Oncology. Honolulu;2019.
Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(Suppl 11):655–68.
pubmed: 28653677
pmcid: 5650537
Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565(Suppl 7741):600–5.
Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(Suppl 6264):1079–84.
pubmed: 26541610
pmcid: 4721659
Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol. 2012;86(Suppl 15):8161–70.
pubmed: 22623779
pmcid: 3421680
Youngblood B, Oestreich Kenneth J, Ha S-J, Duraiswamy J, Akondy Rama S, West Erin E, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8+ T cells. Immunity. 2011;35(Suppl 3):400–12.
pubmed: 21943489
pmcid: 3183460
Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De novo epigenetic programs inhibit Pd-1 blockade-mediated T Cell rejuvenation. Cell. 2017;170(Suppl 1):142–57.e19.
pubmed: 28648661
pmcid: 5568784
Chatterjee A, Rodger EJ, Ahn A, Stockwell PA, Parry M, Motwani J, et al. Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. iScience. 2018;4:312–25.
pubmed: 30240750
pmcid: 6147024
Liu M, Zhou J, Chen Z, Cheng ASL. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. J Pathol. 2016;241:10–24.
pubmed: 27770445
Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice. FASEB J. 2006;20(Suppl 3):506–8.
pubmed: 16407454
pmcid: 2373266
McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(Suppl 7427):108–12.
pubmed: 23051747
pmcid: 23051747
Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, et al. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother. 2018;67(Suppl 3):381–92.
pubmed: 29124315
Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol, Immunother. 2019;68(Suppl 3):379–93.
Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018;10(Suppl 1):93.
pubmed: 30497521
pmcid: 6264032
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(Suppl 4):318–27.
pubmed: 30557521
Chae YK, Anker JF, Carneiro BA, Chandra S, Kaplan J, Kalyan A, et al. Genomic landscape of DNA repair genes in cancer. Oncotarget. 2016;7(Suppl 17):23312.
pubmed: 27004405
pmcid: 5029628
Levine DA, Network CGAR. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(Suppl 7447):67.
pubmed: 23636398
pmcid: 3704730
Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28(Suppl 4):505.
pubmed: 25394778
Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33(Suppl 9):975–7.
pubmed: 25667288